Don’t get too excited. The discovery is specific to autism and schizophrenia associated with 22q11.2 deletion syndrome although this may give insight into other forms of these illnesses.
This significant discovery opens prospects for developing innovative therapeutic approaches aimed at preventing or alleviating symptoms not only in people with 22q11.2 deletion syndrome but potentially in other neurodevelopmental disorders as well.